Journal
HUMAN VACCINES
Volume 5, Issue 12, Pages 832-838Publisher
LANDES BIOSCIENCE
DOI: 10.4161/hv.10297
Keywords
public health; Francisella; tularemia; vaccine; bacteria; infection; biodefense
Categories
Funding
- NIAID NIH HHS [U01 AI077909, U54 AI057168-02, U54 AI057168-07, U54 AI057168-06, U01 AI077909-02, U54 AI057168-03, U01 AI077909-01, U54 AI057168, U54 AI057168-01, U54 AI057168-05, U54 AI057168-08, U54 AI057168-04] Funding Source: Medline
Ask authors/readers for more resources
Francisella tularensis is a Category A select agent for which vaccine and countermeasure development are a priority. In the past eight years, renewed interest in this pathogen has led to the generation of an enormous amount of new data on both the pathogen itself and its interaction with host cells. This information has fostered the development of various vaccine candidates including acellular subunit, killed whole cell and live attenuated. This review summarizes the progress and promise of these various candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
